Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
A prescription is required from a licensed medical provider.
After weighting, the use of GLP-1 receptor agonists was not associated with an increased risk of suicidality compared with DPP-4 inhibitors (weighted incidence rate 3.9 (95% CI 3.5 to 4.4) v 3.7 (3.6 to 3.9) per 1000 person years, respectively
Contact your GP if body odour changes are accompanied by persistent vomiting, signs of dehydration, unexplained fever, severe abdominal pain, or a sweet fruity odour (particularly if you have diabetes), as these may indicate conditions requiring medical assessment
Combining the two may make side effects more severe
Patients with slower hepatic clearance or higher body mass may experience longer drug accumulation, making timing deviations more significant
This suggests that while the warning is in place due to animal data, the actual risk in humans appears to be minimal based on current evidence
